Public Sector Pension Investment Board Purchases 3,464 Shares of IQVIA Holdings Inc. $IQV

Public Sector Pension Investment Board lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 31.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,556 shares of the medical research company’s stock after purchasing an additional 3,464 shares during the period. Public Sector Pension Investment Board’s holdings in IQVIA were worth $2,765,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Physician Wealth Advisors Inc. lifted its position in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares in the last quarter. Westside Investment Management Inc. increased its position in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp bought a new stake in IQVIA during the third quarter worth $36,000. Asset Dedication LLC boosted its position in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after purchasing an additional 168 shares during the last quarter. Finally, Rothschild Investment LLC grew its stake in IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares during the period. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on IQV shares. UBS Group lowered their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Citigroup lowered their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Barclays reduced their target price on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Friday, February 6th. Truist Financial lowered their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Mizuho set a $266.00 price objective on IQVIA in a report on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.20.

IQVIA Stock Performance

Shares of IQV stock opened at $165.63 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The stock has a market capitalization of $28.11 billion, a P/E ratio of 21.07, a PEG ratio of 1.59 and a beta of 1.37. The company has a current ratio of 0.75, a quick ratio of 0.70 and a debt-to-equity ratio of 2.09. The firm’s 50 day moving average is $217.61 and its 200 day moving average is $208.44.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.